VSTM – Verastem, Inc.
Float Short %
27.96
Margin Of Safety %
Put/Call OI Ratio
0.22
EPS Next Q Diff
-0.22
EPS Last/This Y
1.23
EPS This/Next Y
0.49
Price
9.72
Target Price
15.5
Analyst Recom
1
Performance Q
65.31
Relative Volume
0.65
Beta
0.91
Ticker: VSTM
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-08-15 | VSTM | 8.23 | 0.25 | 0.01 | 28245 |
| 2025-08-18 | VSTM | 7.97 | 0.14 | 0.47 | 20291 |
| 2025-08-19 | VSTM | 7.79 | 0.17 | 8.98 | 21810 |
| 2025-08-20 | VSTM | 8.31 | 0.19 | 0.34 | 22245 |
| 2025-08-21 | VSTM | 8.62 | 0.19 | 0.13 | 22381 |
| 2025-08-22 | VSTM | 9.07 | 0.19 | 0.01 | 22192 |
| 2025-08-25 | VSTM | 8.98 | 0.17 | 0.01 | 25313 |
| 2025-08-26 | VSTM | 8.89 | 0.16 | 0.54 | 25682 |
| 2025-08-27 | VSTM | 9.29 | 0.16 | 1.02 | 25683 |
| 2025-08-28 | VSTM | 9.23 | 0.17 | 1.37 | 25696 |
| 2025-08-29 | VSTM | 9.24 | 0.18 | 0.00 | 25790 |
| 2025-09-02 | VSTM | 9.2 | 0.18 | 0.00 | 25803 |
| 2025-09-03 | VSTM | 9.51 | 0.18 | 0.00 | 25837 |
| 2025-09-04 | VSTM | 10.56 | 0.18 | 0.07 | 25847 |
| 2025-09-05 | VSTM | 10.78 | 0.18 | 0.05 | 25901 |
| 2025-09-08 | VSTM | 10.23 | 0.18 | 0.48 | 25860 |
| 2025-09-09 | VSTM | 9.93 | 0.20 | 0.04 | 27508 |
| 2025-09-10 | VSTM | 9.84 | 0.20 | 1.24 | 27514 |
| 2025-09-11 | VSTM | 9.34 | 0.22 | 0.38 | 27828 |
| 2025-09-12 | VSTM | 9.76 | 0.22 | 0.28 | 27935 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-08-15 | VSTM | 8.23 | 27.3 | - | -2.55 |
| 2025-08-18 | VSTM | 7.97 | 27.3 | - | -2.55 |
| 2025-08-19 | VSTM | 7.79 | 27.3 | - | -2.55 |
| 2025-08-20 | VSTM | 8.31 | 27.3 | - | -2.55 |
| 2025-08-21 | VSTM | 8.63 | 27.3 | - | -2.55 |
| 2025-08-22 | VSTM | 9.07 | 30.3 | - | -2.44 |
| 2025-08-25 | VSTM | 8.97 | 30.3 | - | -2.44 |
| 2025-08-26 | VSTM | 8.90 | 30.3 | - | -2.44 |
| 2025-08-27 | VSTM | 9.28 | 30.3 | - | -2.44 |
| 2025-08-28 | VSTM | 9.23 | 30.3 | - | -2.44 |
| 2025-08-29 | VSTM | 9.24 | 30.3 | - | -2.44 |
| 2025-09-02 | VSTM | 9.20 | 30.3 | - | -2.44 |
| 2025-09-03 | VSTM | 9.53 | 30.3 | - | -2.44 |
| 2025-09-04 | VSTM | 10.56 | 30.3 | - | -2.44 |
| 2025-09-05 | VSTM | 10.77 | 30.3 | - | -2.44 |
| 2025-09-08 | VSTM | 10.23 | 30.3 | - | -2.44 |
| 2025-09-09 | VSTM | 9.93 | 30.3 | - | -2.44 |
| 2025-09-10 | VSTM | 9.88 | 30.3 | - | -2.44 |
| 2025-09-11 | VSTM | 9.35 | 30.3 | - | -2.44 |
| 2025-09-12 | VSTM | 9.72 | 30.3 | - | -2.44 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-08-15 | VSTM | -1.40 | 34.15 | 31.13 |
| 2025-08-18 | VSTM | -1.16 | 39.34 | 31.97 |
| 2025-08-19 | VSTM | -1.16 | 39.34 | 30.16 |
| 2025-08-20 | VSTM | -1.89 | 39.34 | 30.16 |
| 2025-08-21 | VSTM | -1.89 | 39.34 | 30.16 |
| 2025-08-22 | VSTM | -1.89 | 39.34 | 30.16 |
| 2025-08-25 | VSTM | -1.89 | 17.79 | 30.16 |
| 2025-08-26 | VSTM | -1.89 | 17.79 | 30.16 |
| 2025-08-27 | VSTM | -1.89 | 17.79 | 28.23 |
| 2025-08-28 | VSTM | -1.89 | 17.79 | 28.23 |
| 2025-08-29 | VSTM | -1.89 | 17.79 | 28.23 |
| 2025-09-02 | VSTM | -1.89 | 17.35 | 28.23 |
| 2025-09-03 | VSTM | -1.89 | 17.35 | 28.23 |
| 2025-09-04 | VSTM | -1.89 | 17.35 | 28.23 |
| 2025-09-05 | VSTM | -1.89 | 17.35 | 28.23 |
| 2025-09-08 | VSTM | -1.89 | 17.35 | 28.23 |
| 2025-09-09 | VSTM | -1.89 | 17.35 | 28.23 |
| 2025-09-10 | VSTM | -1.89 | 17.35 | 28.23 |
| 2025-09-11 | VSTM | -1.89 | 17.35 | 28.23 |
| 2025-09-12 | VSTM | -1.89 | 17.35 | 27.96 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.39
Avg. EPS Est. Current Quarter
-0.61
Avg. EPS Est. Next Quarter
-0.61
Insider Transactions
-1.89
Institutional Transactions
17.35
Beta
0.91
Average Sales Estimate Current Quarter
5
Average Sales Estimate Next Quarter
10
Fair Value
Quality Score
10
Growth Score
32
Sentiment Score
44
Actual DrawDown %
83.6
Max Drawdown 5-Year %
-96.2
Target Price
15.5
P/E
Forward P/E
PEG
P/S
279.54
P/B
16.59
P/Free Cash Flow
EPS
-3.51
Average EPS Est. Cur. Y
-2.44
EPS Next Y. (Est.)
-1.94
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-7793.82
Relative Volume
0.65
Return on Equity vs Sector %
-486.8
Return on Equity vs Industry %
-473.7
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.16
EBIT Estimation
Verastem, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 78
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
stock quote shares VSTM – Verastem, Inc. Stock Price stock today
news today VSTM – Verastem, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VSTM – Verastem, Inc. yahoo finance google finance
stock history VSTM – Verastem, Inc. invest stock market
stock prices VSTM premarket after hours
ticker VSTM fair value insiders trading